Clinical trial NCT01098565: Deep Brain Stimulation Effects Study
Official title: Deep Brain Stimulation Effects: Human Proof-of-Concept Study
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Parkinson's Disease
Lead sponsor: MedtronicNeuro
Sponsor class: INDUSTRY
First posted: 2010-04-02
Enrollment: 6
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP

Brief summary: The purpose of this study is to provide proof-of-concept that the test product can perform as intended in an intra-operative setting and the responses to the test product are perceivable in a person. The study will also compare results of the test product to the commercially-available product.

Hypothesis: the test product will elicit successful test results in over 90% of test product.


Eligibility criteria: Inclusion Criteria:

* Subject is indicated for Activa® DBS implant for the treatment of Parkinson's disease and scheduled for surgery at the study site.
* Subject is willing to sign the informed consent to participate in the study.
* Subject is 18 years of age or older.
* Subject is a male or non-pregnant female.
* Subject has no factors that would put the subject at an additional risk for intra-operative or postoperative bleeding. This includes underlying disorders of the coagulation cascade (eg, hemophilia), disorders that affect platelet count or function (eg, Von Willebrand's disease), as well as administration of any anti-platelet or anti-coagulant medication in the 7 days prior to surgery, or any history of anticoagulant or aspirin use, that in the view of the neurosurgeon or neurologist would place the subject at an increased risk for intra-operative or postoperative bleeding.

Exclusion Criteria:

* Subject is indicated for DBS for treating a disorder other than Parkinson's disease.
* Subject has any medical contraindications to undergoing DBS surgery, (eg, infection, coagulopathy, or significant cardiac or other medical risk factors for surgery).
* Subject has a history of hemorrhagic stroke.
* Subject has a history of a neurosurgical ablation procedure.
* Subject is currently enrolled in or plans to enroll in any concurrent study that may confound the results of this study, as determined by the investigator or Medtronic.
* Subject has a diagnosis of acute myocardial infarction or cardiac arrest less than or equal to 6 months prior to the screening testing.
* Subject has a history of a seizure disorder
* Subject requires short surgery time due to general health issues, as determined by the investigator.
* Subject is a woman who is pregnant or planning to become pregnant, or a woman of child-bearing potential, who is not using a medically-acceptable method of birth control. Women of child-bearing potential must undergo a pregnancy test, with a clear negative result, no more than 7 days prior to the investigational procedure visit.

Primary outcomes:
measure: The HFR0001 device can elicit distinct intra-operative responses in subject symptoms.
timeFrame: 9 months
Secondary outcomes:
measure: Adverse events that occur with the acute implantation and intra-operative testing of the study device.
timeFrame: 9 months.
Other outcomes:
Locations:
city: Kiel
country: Germany
facility: Christian Albrechts University of Kiel
Study officials:
affiliation: University Clinics Kiel, Department of Neurosurgery
name: H. Maximilian Mehdorn, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: